Please login to the form below

Not currently logged in

Pfizer to close six research centres

Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth
Pfizer is to close six research and development facilities in the UK and US as part of its recent acquisition of Wyeth.

The remaining 14 out of the original 20 facilities will be consolidated into five main campuses and nine specialised units.

R&D operations will be eliminated in Gosport and Slough/Taplow in the UK; Princeton, New Jersey; Chazy, Rouses Point and Plattsburgh, New York; and Sanford and Research Triangle Park, North Carolina in the US.

Activities will also be significantly reduced at Collegeville, Pennsylvania; Pearl River, New York; and St Louis, Missouri. In addition, Pfizer will consolidate R&D functions from its New London, Connecticut site to its nearby research facility in Groton.

The restructuring will focus Pfizer's research activities on three main areas of biotherapeutics, pharmatherapeutics and vaccines, supported by specialised units such as monoclonal antibody discovery and regenerative medicine.

The five main research sites include Sandwich in Kent (UK); Cambridge, Massachusetts; Groton, Connecticut; Pearl River, New York; and La Jolla, California.

A broad outline of the restructure was announced back in April, when Wyeth stated that it expected a workforce reduction of 15 per cent – approximately 19,000 positions – as a result of the merger.

10th November 2009


Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...